Table 1.

Common AEs Associated with Vandetanib and Cabozantinib in Order of Frequency (19, 20)

Vandetanib	Cabozantinib
Diarrhea, 57%	Diarrhea, 63%
Rash, 53%	Stomatitis, 51%
Dermatitis acneiform/acne, 35%	Hand-foot skin reaction,50%
Nausea, 33%	Weight loss, 48%
Hypertension, 33%	Decreased appetite, 46%
Headache, 26%	Nausea, 43%
Fatigue, 24%	Fatigue, 41%
Decreased appetite, 21%	Dysgeusia, 34%
Abdominal pain, 21%	Hair color changes/graying, 34%
Dry skin, 15%	Hypertension, 33%
Vomiting, 15%	Constipation, 27%
QT prolongation, 14%a	Abdominal pain, 27%
Photosensitivity reaction, 13%	Vomiting, 24%
	Dysphonia, 20%
Pruritus, 11%	Headache, 18%
Dyspepsia, 11%	Dysphagia, 13%
Proteinuria, 10%	Dyspepsia, 11%
Depression, 10%

^aSixty-nine percent had QTc prolongation > 450 ms and 7% had QTc > 500 ms using the Fridericia correction.